Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 53

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 53
---
, the Company will apply to cease to be a reporting issuer in Canada and the Common Shares will be delisted from Nasdaq and deregistered under the Exchange Act, in each case, in accordance with applicable Laws, rules and regulations. Following completion of the Arrangement and such deregistration, the Company will no longer file periodic reports with the SEC. The Arrangement will be carried out pursuant to the terms of the Agreement and the Plan of Arrangement. Background of the Arrangement The following background summarizes the key meetings and events that led to the execution of the Agreement. This background does not purport to catalog every conversation of or among the Transaction Committee, the Board, their representatives or other parties. The Board, together with its management, regularly evaluated the Company’s strategic direction and ongoing business plans, with a view towards strengthening the Company’s business and enhancing shareholder value. This evaluation took into account several factors, including the financial condition of the Company, the competitive industry in which the Company operates, the development of the Company’s product candidates, pipeline and other considerations. As part of this evaluation, from time to time, the Board and the Company’s management reviewed a variety of potential strategic alternatives, including the continuation of, and potential improvements to, the Company’s current business plans, with the Company continuing as a going concern, capital raising activities, and potential business combinations, partnerships, licenses, collaborations and other 29

financial and strategic transactions, including the potential sale of the Company or certain of its assets. Further, the Company regularly engaged in business development outreach around its (i) RP-3467 and Polq program, (ii) RP-1664 program and (iii) RP-3500
(camonsertib) program.

In January 2025, the Company announced a re-alignment of resources, a re-prioritization of its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-1664 (PLK4 inhibitor) and
RP-3467 (Polq ATPase inhibitor), its intention to seek partnering opportunities across its portfolio, including for lunresertib and camonsertib, as well as planned
cost and headcount reductions in connection therewith. Following an initial focus on achieving near-term inflection points for its Phase 1 clinical assets to create value, in March 2025, the Company announced that it was reducing its workforce by
approximately 75% to extend its cash runway into late 2027.

Following such events, the Company formed